Alps Group, Inc. operates as a biotechnology company that integrates research and development, medical services, and wellness solutions. The company is headquartered in Kuala Lumpur, Wilayah Persekutuan. The company went IPO on 2025-10-31. The firm has cultivated a diverse pipeline covering various biotechnology research areas. This includes initiatives focused on MyImmune (NK cells), CAR-T cells, COVID-19 mRNA vaccine, diabetes therapeutics, and advancements in stem cell technologies such as induced Pluripotent Stem Cells (iPSCs) and messenger ribonucleic acid (mRNA) platform technology. The firm provides aesthetic treatments, cosmetic procedures, general healthcare and wellness services. The Company’s aesthetic services and cosmetic surgery services include non-surgical aesthetic services and surgical aesthetic services. The company operates a molecular laboratory and a cGMP cell and gene therapy research and cultivation laboratory.
How did GLLIR's recent EPS compare to expectations?
The most recent EPS for Alps Group Inc is $, expectations of $.
How did Alps Group Inc GLLIR's revenue perform in the last quarter?
Alps Group Inc revenue for the last quarter is $
What is the revenue estimate for Alps Group Inc?
According to of Wall street analyst, the revenue estimate of Alps Group Inc range from $ to $
What's the earning quality score for Alps Group Inc?
Alps Group Inc has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Alps Group Inc report earnings?
Alps Group Inc next earnings report is expected in 2026-06-15
What are Alps Group Inc's expected earnings?
Alps Group Inc expected earnings is $, according to wall-street analysts.